Abstract
Brachytherapy (intraluminal radiotherapy) has been in use for more than two decades as a boost after external beam radiation for the definitive treatment of esophageal carcinoma. Recent studies have suggested that brachytherapy alone could be a promising therapy for the palliation of dysphagia caused by inoperable esophageal carcinoma. Single-dose brachytherapy has been shown to be not only more effective but also a safer palliative treatment for dysphagia than stent placement, which is currently the most widely used palliative treatment for esophageal cancer, and the wider use of brachytherapy in this setting is therefore warranted.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
